PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
spond to a collection of information unless it contains a vatid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	Divisional of 10/268,059
INF	ORMATI	ON DIS	CLOSURE	Filing Date	February 5, 2004
ST	ATEMEN.	T BY A	PPLICANT	First Named Inventor	David Edwards
				Art Unit	N/A
	(Use as many	y sheets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	000166.0109-US02

[U.S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KM	AA	US-3,635,219-B1	01/1972	Altounyan et al.	
-	AB	US-3,669,113-B1	06/1972	Altounyan et al.	
	AC	US-3,795,244-B1	03/1974	Lax et al.	
	AD	US-3,837,341-B1	09/1974	Bell	
	AE	US-3,888,253-B1	06/1975	Watt et al.	
	AF	US-3,906,950	09/1975	Cocozza	
	AG**	US-4,013,075	03/1977	Cocozza	
	AH	US-4.069,228	01/1978	Valentini et al.	
	Al	US-4,069,819-B1	01/1978	Valentini et al.	
	AJ	US-4,105,027-B1	08/1978	Lundquist	
	AK	US-4,192,309	03/1980	Poulsen	
	AL	US-4,240,418	12/1980	Rosskamp et al.	
	AM	US-4,860,740	08/1989	Kirk et al.	
	AN	US-4,889,114-B1	12/1989	Kladders	
-	AO	US-4,995,285	02/1991	Valentini et al.	
\neg	AP	US-5,152,284-B1	10/1992	Valentini et al.	
	AQ	US-5,239,992-B1	08/1993	Bougamont et al.	
	AR	US-5,301,666-B1	04/1994	Lerk et al.	
	AS	US-5.349.947	09/1994	Newhouse et al.	
	AT	US-5,595,175-B1	01/1997	Malcher et al.	
	AU	US-5,647,349	07/1997	Ohki et al.	
	AV	US-5.651,359	07/1997	Bougamont et al.	1
	AW	US-5,673,686-B1	10/1997	Villax et al.	
	AX	US-5,685,294	11/1997	Gupte et al.	
	AY	US-5,727,546	03/1998	Clarke et al.	
	AZ	US-5,740,794	04/1998	Smith et al.	
	AA1	US-5,785,049	07/1998	Smith et al.	
		US-5,797,391	08/1998	Cook et al.	1
		US-5,810,004	09/1998	Ohki et al.	
		US-5,860,419	01/1999	Davies et al.	
	AE1	US-5,896,855-B1	04/1999	Hobbs et al.	
1	AF1	US-5,921,237	07/1999	Eisele et al.	
		US-6,089,228	07/2000	Smith et al.	
		US-6,092,522-B1	07/2000	Calvert et al.	
	Al1	US-6.102.035	08/2000	Asking et al.	
\vdash	AJ1	US-6,116,237-B1	09/2000	Schultz et al.	
1/		US-6.116,238-B1	09/2000	Jackson et al.	
-V-	AL1	US-6.142.145	11/2000	Dagsland et al.	-
KM		US-US 2003/0094173-A1	05-22-2003	Burr et al.	·

Examiner Signature	/Kristen Matter/	Date Considered	10/12/2006

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
spond to a collection of thromration unless it contains a vetid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
0000	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Application Number	Divisional f 10/268,059	
IN	FORMATIC	ON DIS	CLOSURE	Filing Date	February 5, 2004	
STATEMENT BY APPLICANT				First Named Inventor	David Edwards	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	000166.0109-US02	

		FOREI	GN PATENT	DOCUMENTS		
		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Date MM-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	™
	BA	EA-0 407 276-A2	01/1991	VALOIS Societe Anonyme		
				dite		
	88	EP-0 500 292-A1	09/1992	Rhone-Poulenc Rorer Limited		
	BC	WO WO 04/08552 A2	04/1004	Mocikalski et al.		-
	80	WF-WO 00/04519-A1	11/2000	Haikarainen et al.		•
	BF	WO-WO 01/07107	02/2001	Pharmaceutical Discovery		
				Corporation		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "CITE NO.: Those patent(s) or publication(s) which are marked with an doubte asterisk (") next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.pspto.org/ or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-issue number(s), publisher, city and/or country where published.	T²
	CA	Risgaard H et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in	L
		children with asthma, European Respiratory Journal, 11: 1111-1115 (May 1998).	
	СВ	de Boer, A.H. et al., "Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers, Part 1. Inhalation characteristics, work on breathing and volunteers'	
		preference in dependence of the inhaler resistance," International Journal of Pharmaceutics 130: 231-244 (1996).	
	СС	Dunbar, Craig A. et al., A Comparison of Dry Powder Inhaler Dose Delivery Characteristics Using a Power Griterion, PDA Journal of Pharmaceutical Science & Technology, 54(8).	
		4780484 (November/December 2000).	
	CD	Feddah, Majid R. et al., In-Vitro Characterisation of Metered Dose Inhaler Versus Dry Powder	T
_		Inhale: Slucocorticoid Products. Influence of Inspiratory Plow Rates, J. Pham. Pharmaceut. Sci. (www.ualberta.ca/-csps) 3(3): 317-324 (2000).	Γ
	CE	Koskela, T. et al., Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow,	
	1	Respiratory Medicine 94: 1229-1233 (December 2000).	
	CF	Nielsen, K.G. et al., Flow-dependent effect of formoterol dry-powder inhaled from the	┺
		Aerolizer®, European Respiratory Journal, 10: 2105-2109 (September 1997).	
	CG	Richards, Robert and Saunders, Michael, Need for a comparative performance standard for	<u> </u>
		dry powder inhalers, Thorax 48: 1186-1187 (November 1993).	
	СН	Ross, Danna L. and Schultz, Robert K., Effect of Inhalation Flow Rate on the Dosing	
		Characteristics of Dry Powder Inhator (DPI) and Metered Bose Inhator (MDI) Producte, Journal of Aerosol Medicine, 9: 215-226 (November 2, 1996).	<u> </u>
	Ci	Smith, Karen J. et al., Influence of Flow Rate on Aerosole Particle Size Distributions from	T
		Pressurized and Breath-Actuated Innalers, Journal of Aerosol Medicine, 11: 231-245 (November 4, 1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached.

Examiner /Kristen Matter/	Date - 10/12/2006
 Olgitato O	